Purpose To evaluate the effect of the nonsteroidal antiinflammatory drugs tolfenamic acid and flunixin meglumine in pregnancy rate and embryo survival of recipient mice subjected to embryo transfer. Methods A total of 142 recipient females were transferred with 2,931 embryos and treated with a single injection of tolfenamic acid (1 mg/kg; n=54 females with 1,129 embryos), flunixin meglumine (2.5 mg/kg; n=46 females with 942 embryos), or bi-distilled water (10 mL/kg) as control group (n=42 females with 860 embryos). Pregnancy was checked 2 weeks after embryo transfer, delivery was registered on the due date, and litter size was recorded on Day 7 after birth. Results Pregnancy rate of tolfenamic acid treated females was significantly higher than flunixin group (P<0.05) and showed a tendency to be higher when compared to the control group (P=0.06). The number of pups born from transferred embryos in pregnant females was significantly higher for both treatment groups compared to controls (P<0.05). Number of pups from total transferred embryos was higher for both treatment groups (P<0.05) when compared to controls. Conclusion The use of tolfenamic acid at the time of embryo transfer improves both pregnancy rate and number of live pups in recipient mice, with optimal effects observed with flunixin meglumine. We suggest that the use of tolfenamic acid has beneficial effects on the maintenance of pregnancy and embryo survival in recipient mice, which should be taken into account for further studies in other mammalian females.
Introduction
Pain relief is essential in surgical procedures since it optimizes postoperative care and well-being of animals [1] . In this sense, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) includes anti-inflammatory, analgesic and antipyretic effects, via inhibition of cyclooxygenase (COX) enzyme, particularly COX-2, which plays a major role in prostaglandin (PG) synthesis [2, 3] . During embryo transfer, manipulation of the reproductive tract produces an inflammatory process which could be induced by the embryo itself, by transfer media acting as foreign material and/or by microorganisms introduced into the uterus during surgery [4] . It has been shown that embryo transfer causes release of PGF2α which has deleterious effects on luteal function and embryo survival [5, 6] . Since PGF2α is the main hormone that triggers luteolysis [7] , it could indirectly cause embryonic loss before maternal recognition of pregnancy. Furthermore, addition of PGF2α to the culture medium has shown to inhibit in vitro development of rabbit [8] and bovine embryos [9] . Thus, in mammalian females the inhibition of endometrial PGF2alpha release or the blockage of its action contributes to maintain luteal function, embryo survival and establishment of pregnancy.
Flunixin meglumine, a commonly used NSAID, has been previously used to reduce the inflammatory process during embryo transfer in some species. Koblischke et al. determined that administration of flunixin meglumine or meclofenamic acid to recipient mares produced a significant reduction of COX-2 positive cells and polimorphonuclear cell recruitment in the endometrium, and also a reduction of PGF2α concentration in plasma was observed when meclofenamic acid was used. These phenomena were accompanied by a lower incidence of luteolysis [4] . Also, Santos et al. reported that inhibition of PGF2α synthesis with flunixin meglumine interferes with luteolysis and leads to prolonged luteal activity in mares [10] . Flunixin meglumine have also been proposed to improve pregnancy in farm animals. Koblischke et al. detected higher pregnancy rates of mares receiving flunixin meglumine and vedaprofen simultaneously when compared to untreated mares [5] . In cattle, administration of flunixin meglumine at the time of embryo transfer or before maternal recognition of gestation increased pregnancy rates according to Scenna et al. [6] and Guzeloglu et al. [11] although, similar studies did not show beneficial effects of flunixin meglumine treatment in bovines [12, 13] . In mice, it has been shown that flunixin meglumine has no detrimental effects on embryonic survival and implantation [14] , but possible beneficial effects of flunixin meglumine or other NSAIDs in pregnancy have not been reported yet.
Tolfenamic acid is a NSAID that has never been reported in recipient females. This drug differs from flunixin meglumine in their chemical structure: flunixin meglumine is an amino nicotinic acid derivate and tolfenamic acid belongs to the anthranilic acid subgroup, also known as fenamates. These NSAIDs also show some differences in the COX isoform selectivity. Tolfenamic acid preferentially inhibits COX-2 in dogs [15] and goats [16] , whereas flunixin meglumine does not show specific inhibition [17] . Tolfenamic acid not only inhibits COX but also 5-1ipoxygenase, both enzymes are involved in the pathways of arachidonic acid metabolism [18, 19] . Fenamates are also low-potency modulators of a diversity of ion channels and enzymes, exhibiting either activator or inhibitory effects [20] . The use of tolfenamic acid in recipient females at embryo transfer to improve the maintenance of the pregnancy has not been proposed in any specie.
The objective of this study was to evaluate the effect of tolfenamic acid and flunixin meglumine administration on pregnancy rate and embryo survival after embryo transfer surgery in recipient mice used in a transgenic animal facility. 
Materials and methods

Animals
Embryo collection
Ovarian superstimulation was induced in 3-4 week-old B6SJL F1 or C57BL6/J donor females with a single intraperitoneal (i.p.) injection of 5 IU of equine chorionic gonadotrophin (eCG; Novormon®, Syntex, Buenos Aires, Argentina) and 5 IU of human chorionic gonadotrophin (hCG; Chorulon®, Intervet International B.V., Boxmeer, Holland) 46 h later. Soon after hCG treatment, females were mated with adult male mice in 1:1 ratio. For microinjection, donor females were euthanized by cervical dislocation 12 h after mating, oviducts were excised and onecell embryos were collected from the swollen ampulla in M2 medium containing 0.3 mg/ml hyaluronidase to remove cumulus cells. For rederivation, females were euthanized by cervical dislocation 36 h after mating and embryos collected by oviduct flushing. All embryos were cultured in M16 medium microdrops under embryo tested mineral oil, in 5 % CO 2 in air at 37°C [22] . Unless otherwise indicated, chemicals were purchased from Sigma Chemical Company (St Louis, MO, USA).
Pronuclear microinjection
Pronuclear microinjection was performed using an inverted microscope (TE 2000, Nikon, NY, USA) and mechanical micromanipulators (Transferman NK2, Eppendorf, Hamburg, Germany) using embryo holding pipettes (35°bent angle, opening diameter of 20-25 μm; Biomedical Instruments, Zöllnitz, Germany) and home-made injection pipettes. Since the embryos were produced for the establishment of different transgenic lines in our laboratory, different linearized DNA vectors were injected at 2 ng/μl diluted in microinjection buffer (5 mM Tris-HCl, pH 7.4, 0.1 mM EDTA) [22] . For each microinjection session, 100-150 zygotes were loaded in groups of 30 in glass depression slides containing M2 medium under mineral oil. DNA solution was injected into the male or female pronucleus, until the pronuclear membrane visibly swelled. After microinjection, embryos were maintained in the aforementioned culture conditions for 30 min to evaluate survival rate before being transferred to foster mothers. Surviving zygotes were defined according to standard criteria [23] .
Embryo transfer
All foster mothers (Swiss and B6D2 F1) were mated with vasectomized adult males with proven sterility to induce pseudopregnancy and were checked for copulatory plugs the day of embryo transfer. Embryo transfer was performed within 30 min after microinjection or 2-3 h after oviduct flushing for the rederived embryos. The recipient females were anesthetized with a mixture of ketamine (100 mg/kg; Vetanarcol®, König, Buenos Aires, Argentina) and xylazine (10 mg/kg; Seton®, Calier, Barcelona, Spain) via i.p. [24] . The embryos were loaded into a pulled glass pipette and placed through the infundibulum into both oviducts, transferring in average 15 rederived or 23 microinjected embryos per female. For surgery and recovery procedures, females were placed over a warm pad to avoid hypothermia [22] .
Experimental design
A total of 142 Swiss and B6D2 foster females at 0.5 dpc were transferred with microinjected or rederived embryos. For each embryo transfer session recipients were randomly assigned to one of the following three groups: tolfenamic acid (TA) group (n=54 females, 1,129 embryos), flunixin meglumine (FM) group (n=46 females, 942 embryos), or control group (n=42 females, 860 embryos). The treatment was performed in a single subcutaneous injection of tolfenamic acid (1 mg/kg of body weight, Tolfedine®, Vetoquinol, Lure, France), flunixin meglumine (2.5 mg/kg of body weight, Niglumine®, Calier, Barcelona, Spain), or sterile bi-distilled apyrogenic water (10 mL/kg of body weight), immediately after embryo transfer and before the foster female came out of anesthetic plane. Pregnancy was determined by visual inspection by an experienced animal caretaker 2 weeks after embryo transfer, delivery rate was registered on the due date, and litter size was recorded on Day 7 after birth.
Statistical analysis
Pregnancy rate (pregnant/transferred recipients), delivery rate (parturition/pregnant recipients), birth rate (live pups/transferred embryos) in pregnant females and birth rate in total females were compared among three experimental groups by logistic regression (SPSS version 18.0). The analysis included the effect of the source of the embryos (i.e. microinjection or rederivation) and data are showed pooled since the results were not affected by this factor. Differences were considered significant for P value <0.05 and <0.1 was assumed as tendency.
Results
The administration of the NSAID tolfenamic acid at the time of embryo transfer showed a tendency (P=0.06) to improve pregnancy rate and improved birth rate in pregnant females (P<0.05) and the number of live pups from total transferred embryos (P<0.05) in comparison to control females (Table 1). The administration of flunixin meglumine did not have a significant effect on pregnancy rate, but improved the birth rate in pregnant females (P<0.05) and the birth rate in total transferred females (P<0.05) in comparison to control females. Interestingly, pregnancy rate was greater in TA group than FM group (P<0.05), but birth rate in pregnant females was greater in FM than TA group (P<0.05). The number of live pups from transferred embryos in total females did not show statistical differences with the administration of tolfenamic acid or flunixin meglumine.
Discussion
In this study, the administration of NSAIDs to mice at the time of embryo transfer significantly improved embryo survival producing greater birth rate than control females. In addition, differences were found between NSAID treatments since tolfenamic acid was more effective than flunixin meglumine in maintaining pregnancy, but flunixin meglumine was more effective in producing live pups in pregnant females.
The effect of tolfenamic acid in recipient females had not been reported yet. However, the use of other NSAIDs at embryo transfer has shown interesting results in some species: the administration of one dose of flunixin meglumine in cows [6] , a single dose of ibuprofen lysinate in heifers [25] , and five doses of flunixin meglumine or meclofenamic acid in mares [4] produced higher pregnancy rates than untreated females. In the studies performed in cows and mares it was demonstrated that NSAIDs reduced PGF2α release after embryo transfer. Moreover, meclofenamic acid, chemically similar to tolfenamic acid, was more effective than flunixin meglumine to inhibit PGF2α release in recipient mares. In this sense, our study shows greater pregnancy rate in tolfenamic acid treated females than flunixin meglumine and is the first report to demonstrate an effect of this NSAID on maintenance of the pregnancy in mammalian females.
The different results obtained for flunixin meglumine and tolfenamic acid could be explained by COX isoform selectivity, taking into account that flunixin meglumine has no specific inhibition whereas tolfenamic acid shows a stronger specificity for COX-2, which has been shown to mainly produce inflammatory responses. In the corpus luteum (CL), different immune mediators and cells are recruited during its lifespan. There is a growing list of potential factors that may be involved in the luteolytic process, including endothelialderived proteins, immune cell-derived cytokines, reactive oxygen species, neuropeptides and lipophilic molecules. Bidirectional communication between luteal and immune cells may thus facilitate hormonally regulated survival and demise of the CL [7, 26] . Both tolfenamic acid and flunixin meglumine could inhibit luteolysis by blocking PG synthesis but tolfenamic acid could also have effects over the immune responses and the survival of CL.
The beneficial effect of NSAIDs at embryo transfer does not only seem to be associated to the anti-luteolytic effect of the treatment. Women undergoing in vitro fertilization (IVF) receiving a daily oral dose of 100 mg of the NSAID acetylsalicylic acid had better ovarian response, uterine and ovarian blood flow velocity, implantation, and pregnancy rates than women receiving placebo [27] . Similar results were found in women undergoing IVF and receiving 75 mg of aspirin daily from the day of embryo transfer until pregnancy test in which higher pregnancy rates were reported [28] . Moreover, treatment of women with piroxicam, an oxicam kind of NSAID, administrated 1-2 h before embryo transfer increased implantation and pregnancy rates, in both fresh and frozen-thawed embryo transfer cycles [29] . The mechanisms involved in these effects are still not clear.
We suggest that tolfenamic acid could improve pregnancy rates in recipient mice by preventing early luteolysis, but also by reducing embryonic loss in those females getting pregnant, an effect probably associated with inflammatory process elicited by uterine manipulation. In addition, flunixin meglumine had positive effect on embryo survival, inducing greater birth rate from pregnant females, almost doubling the values of the control group (i.e. 35.3 % vs. 17.2 %, respectively). Thus, the reduced embryonic loss observed for tolfenamic acid was even more evident for flunixin meglumine.
The positive effect of NSAIDs on embryo survival showed in this study could also be associated with a local effect by the blocking of PG production in the endometrium. It has been demonstrated that development of in vitro produced bovine embryos to blastocyst stage was reduced by addition of PGF2α (1 ng/ml) in the culture media, and that addition of PGF2α to the culture media of in vivo derived bovine embryos in compact morulae stage did not affect development to blastocyst, but reduced hatching rates [9] . In other study, cows were administered with flunixin meglumine at the time of embryo transfer, and pregnancy rates were evaluated by quality score of the embryos. Pregnancy rate with Grade 2 embryos, but not with Grade 1 embryos, was improved following administration of flunixin meglumine [6] . These findings suggest that compromised quality embryos are most susceptible to deleterious effects of PGF2α, an effect that could be prevented by NSAID administration. Scenna et al. proposed that even though release of PGF2α during embryo transfer may not result in luteolysis, embryonic survival may be compromised by the presence of small concentrations of PGF2α in the uterine lumen, creating a hostile environment for embryonic development [6] . In our study, both tolfenamic acid and flunixin meglumine had positive effects on birth rate which could indicate that both NSAIDs could improve uterine environment for embryo development and surviving, although the mechanism of action is not clearly explained.
In conclusion, this study reports for the first time that the use of tolfenamic acid in recipient females at embryo transfer improves the maintenance of pregnancy and embryo survival. In addition, flunixin meglumine improves birth rate but not pregnancy rate, suggesting that its effect is mainly associated with embryo survival instead of luteal maintenance. Overall results show that both NSAIDs, and tolfenamic acid in particular, represent a promising treatment for embryo transfer programs in mammalian females. 
